Latest News & Updates

Breaking News

  • 8 hours ago

  • Vaibhavi M.

Agios Continues Collaboration With FDA To Finalize Mitapivat sNDA Documentation For Thalassemia Treatment
Breaking News
Roche’s Three-Year STARGLO Data Confirm Long-Term Survival Advantage Of Columvi + GemOx In R/R DLBCL; Sustains Strong Efficacy And Safety, Reinforcing Global Adoption

Vaibhavi M.

Other trending news you may like to read

Agios Continues Collaboration With FDA To Finalize Mitapivat sNDA Documentation For Thalassemia Treatment

Agios says FDA has not yet issued a final decision on mitapivat sNDA for alpha and beta thalassemia as labeling and REMS review continues.

Vaibhavi M.

Pharma Now

Roche’s Three-Year STARGLO Data Confirm Long-Term Survival Advantage Of Columvi + GemOx In R/R DLBCL; Sustains Strong Efficacy And Safety, Reinforcing Global Adoption

Roche reports 3-year STARGLO data showing Columvi plus GemOx doubled overall survival in relapsed or refractory DLBCL patients.

Vaibhavi M.

Pharma Now

Praxis Reports Strong EMBOLD And RADIANT Results, Highlighting Rapid And Durable Seizure Reduction Across Programs

Praxis reports positive EMBOLD data for relutrigine, showing strong seizure reduction and favorable safety, and plans FDA meeting for potential NDA.

Vaibhavi M.

Pharma Now

Roche Secures European Commission Approval For Obinutuzumab Combo Therapy, Marking A Major Advancement In Lupus Nephritis Treatment

Roche receives EU approval for Gazyva/Gazyvaro with MMF in active lupus nephritis, offering a new treatment option to slow kidney damage.

Vaibhavi M.

Pharma Now